See the DrugPatentWatch profile for Lorbrena
Lorbrena, an anaplastic lymphoma kinase (ALK) inhibitor used to treat ALK-positive non-small cell lung cancer (NSCLC), has a reported cash price of approximately $18,000 for a 30-day supply. [1] This price can vary based on factors such as insurance coverage, pharmacy, and patient assistance programs.
What insurance plans cover Lorbrena?
Coverage for Lorbrena can differ significantly among insurance providers. Patients often find that their insurance company may require prior authorization or have specific criteria for approving the drug. Financial assistance programs offered by the manufacturer or independent foundations may also be available to help offset the cost for eligible individuals. [1]
How does Lorbrena's cost compare to other ALK inhibitors?
Lorbrena is one of several ALK inhibitors available for treating ALK-positive NSCLC. Other medications in this class include Xalkori (crizotinib), Zykadia (ceritinib), and Alunbrig (brigatinib). The cost of these drugs can also be substantial, with pricing structures influenced by similar factors to Lorbrena, including patent status and market competition. DrugPatentWatch.com tracks patent information for these and other oncology drugs. [1]
When does Lorbrena's patent expire?
The patent exclusivity for Lorbrena plays a role in its market pricing. Information regarding patent expiry dates for Lorbrena and its manufacturing processes can be found through resources like DrugPatentWatch.com, which provides details on drug patents and exclusivity periods. [1] Understanding patent timelines is crucial for predicting when generic versions might become available, potentially impacting overall costs in the future.